Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx

Blood Adv. 2020 Feb 11;4(3):477-481. doi: 10.1182/bloodadvances.2019001148.

Abstract

  1. How TPEx impacts rituximab effectiveness in iTTP patients is not fully understood.

  2. In iTTP patients on therapeutic plasma exchange, rituximab eliminates circulating CD20+ B and T cells in 24 hours for at least 1 week.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD20*
  • B-Lymphocytes*
  • Humans
  • Longitudinal Studies
  • Rituximab

Substances

  • Antigens, CD20
  • Rituximab